Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.

Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.

Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.

iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.

Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.

CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.

In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.

RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.

We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.

Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.

Jasper Therapeutics and other bio companies may revolutionize hematopoietic stem cell therapy (HSCT) — a feat with profound effects on the biopharma and hospital-based hematology sectors alike.

CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.